- Home
- FSP vs IGC Comparison
FSP vs IGC Comparison
Compare FSP & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FSP | IGC |
|---|---|---|
| Founded | 1981 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 32.0M |
| IPO Year | 2001 | 2005 |
Fundamental Metrics
Financial Performance| Metric | FSP | IGC |
|---|---|---|
| Price | $0.37 | $0.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 783.1K | 622.9K |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | 15.69 | ★ 59.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $107,162,000.00 | $1,271,000.00 |
| Revenue This Year | $16.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $0.24 |
| 52 Week High | $1.49 | $0.45 |
Technical Indicators
Market Signals| Indicator | FSP | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 53.44 | 47.45 |
| Support Level | $0.32 | $0.27 |
| Resistance Level | $0.38 | $0.30 |
| Average True Range (ATR) | 0.02 | 0.01 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 76.74 | 32.06 |
Price Performance
Historical ComparisonAbout FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.